GlassScriptPhysician profile
Phylis Muthee
NPI 1598015919
$3,099.45
in general payments reported to CMS, 2019-2025
32 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what 85% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,493 · 2022: $109 · 2023: $153 · 2024: $332 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,497.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $710.88 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $459.95 | 2021-2025 | Airsupra |
| Gilead Sciences, INC. | $216.80 | 2024-2025 | Yeztugo |
| Sunovion Pharmaceuticals INC. | $179.86 | 2021 | |
| Lilly USA, LLC | $141.70 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Edwards Lifesciences Corporation | $134.80 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbvie INC. | $131.05 | 2025 | |
| Viiv Healthcare Company | $118.15 | 2025 | Apretude |
| Alk-Abello, INC | $114.20 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.50 | 2021 | |
| Novartis Pharmaceuticals Corporation | $106.17 | 2021 | |
| Neurocrine Biosciences, INC. | $63.87 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.88 | 2021 | |
| Biogen, INC. | $51.58 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $48.83 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $47.25 | 2021 | |
| Glaxosmithkline, LLC. | $44.28 | 2021-2022 | |
| Neurelis, INC. | $41.16 | 2021 | |
| Janssen Pharmaceuticals, INC | $38.88 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.13 | 2025 | |
| Amarin Pharma, INC. | $27.74 | 2021 | |
| Sun Pharmaceutical Industries INC. | $24.79 | 2021 | |
| Vifor Pharma, INC. | $24.22 | 2021 | |
| Endo Pharmaceuticals INC. | $23.83 | 2021 | |
| Exact Sciences Corporation | $22.31 | 2025 | The Cologuard Plus Collection Kit |
| Abbott Laboratories | $20.86 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.62 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.34 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.19 | 2021 | |
| Pfizer INC. | $17.99 | 2021 | |
| Eisai INC. | $15.41 | 2021 | |
| Acadia Pharmaceuticals INC | $12.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phylis Muthee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.